profit from every $100 of sales.
$0$100
Xtant Medical Holdings
$0.27-1.31% today
-58.8% in 1 year
1-year low $0.271-year high $0.81
Trading close to its lowest price of the past year.
The essentials
Four questions every investor asks, answered in one line each.
more sales each year, on average, 2022 to 2025.
0%20% a year
You pay $7.66 for every $1 of profit it makes in a year.
CheapExpensive
of earnings would pay off all its debt.
No debt5 years
Money in, money out
What Xtant Medical Holdings sold, what it kept, and what it did with the cash.
Sales went from $58.0 million in 2022 to $134 million in 2025, with $4.97 million of profit last year.
SalesProfit
Xtant Medical Holdings handed back 1% of the cash it generated last year.
Buybacks $65,000
Free cash flow 2025$10M
Bought back its own shares$65,000
Paid as dividends–
Cash vs. debt$17M vs. $29M
Xtant Medical Holdings vs. similar companies
Xtant Medical Holdings grows the fastest of these 5 and is the cheapest for its profits.
| Company | Profit from $100 of sales | Sales growth a year | Price per $1 of profit |
|---|---|---|---|
| Xtant Medical Holdings | 7.7× · Cheap | ||
 Boston Scientific | 22.2× · Fair price | ||
 Koninklijke Philips | 30.1× · Expensive | ||
 Steris | 32.8× · Expensive | ||
 Zimmer Biomet Holdings | 27.7× · Fair price |
AI analysis
An AI analyst reads Xtant Medical Holdings's last five years, its segments, earnings, insiders and peers, and writes the bull case, the bear case and what the price expects.
Run the AI analysisFull statementsIncome, balance sheet and cash flow, year by year
Income statement
| In millions of USD | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| 58 | 91 | 117 | 134 | |
| 32 | 55 | 68 | 84 | |
| -7 | -10 | -12 | 7 | |
| -5 | 5 | -8 | 16 | |
| -8 | 1 | -16 | 5 | |
| -0.09 | 0.01 | -0.12 | 0.03 | |
| 55.4% | 60.8% | 58.2% | 62.9% | |
| -11.7% | -11.1% | -10.3% | 5.4% | |
| -14.6% | 0.7% | -14.0% | 3.7% |
Balance sheet
| In millions of USD | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Total assets | 60 | 93 | 94 | 94 |
| Cash | 20 | 6 | 6 | 17 |
| Total debt | 17 | 24 | 35 | 29 |
| Total liabilities | 26 | 41 | 51 | 43 |
| 34 | 51 | 43 | 51 | |
| 94 | 127 | 134 | 150 | |
| -10.4% | 2.0% | -12.2% | 10.6% | |
| -24.8% | 1.3% | -38.3% | 9.8% |
Cash flow
| In millions of USD | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| -5 | -10 | -12 | 13 | |
| 2 | 1 | 4 | 2 | |
| -7 | -11 | -16 | 10 | |
| Dividends paid | – | – | – | – |
| – | – | – | 0 | |
| 2 | 3 | 4 | 3 |
Valuation
- 7.7×
- 27.2×
- –
- 1.4×
- 0.3×
- 3.8×
- 3.1×
- 26.7%
- 13.0%
- 0.0%
Profitability
- 62.9%
- 5.4%
- 3.7%
- 11.9%
- 6.5%
- -8.1%
- 10.3%
- 5.3%
- 11.3%
- 1.6%
Growth
- +32.2%
- –
- +163.5%
- –
- +13.0%
Financial health
- 0.7×
- 0.56
- 30.5%
- 2.0×
- 2.65
- 1.63
- 1.42
How it ranks in Healthcare
Each dot is where the company stands among every company over $300M in the sector. Further right is better.
Top 44%of 946
Bottom 41%of 872
Top 7%of 563
Top 18%of 868
Top 2%of 986
What analysts expect
- Average price target
- $1.50
- Range
- $1.50 – $1.50
These targets were collected on May 20, 2026 and our analyst feed has not updated since, so we no longer compare them with today's price.
Recent earnings
Our results feed has not updated since May 21, 2026. Results reported after that are not in this table yet.
| Date | EPS | Expected | Surprise |
|---|---|---|---|
| May 13, 2026 | -0.02 | -0.02 | −33.3% |
| Mar 31, 2026 | 0.00 | -0.00 | +108.2% |
| Nov 10, 2025 | 0.01 | -0.01 | +290.5% |
| Aug 12, 2025 | 0.02 | -0.01 | +300.0% |
| May 12, 2025 | 0.00 | -0.01 | +104.0% |
| Mar 6, 2025 | -0.02 | -0.01 | −100.0% |
| Nov 12, 2024 | -0.04 | -0.03 | −60.0% |
| Aug 8, 2024 | -0.03 | -0.02 | −50.0% |
News
No recent news on file.
Insider trades
Our insider feed has not updated since May 26, 2026. Trades filed after that are not listed yet.
No insider trades on file.
The seven classic investing rulebooks
2/7Passes 2 of 7. Each bar is how well the company fits that investor's published rules, from 0 to 100; 60 or more counts as a pass.
Warren Buffett
59No pass
Benjamin Graham
71Pass
Philip Fisher
57No pass
Peter Lynch
76Pass
Joel Greenblatt
59No pass
Charlie Munger
40No pass
Terry Smith
50No pass
Questions about Xtant Medical Holdings
Is Xtant Medical Holdings a good stock to buy?
A business with weak numbers, and the price looks low. 2 of the 7 famous investors' published rulebooks we apply pass it. Whether it suits you depends on your goals and the price you pay; invest-like never tells anyone to buy or sell. The AI analysis lays out the case for and against. Read the Xtant Medical Holdings AI analysis
What does Xtant Medical Holdings do?
Xtant Medical Holdings, Inc. develops, manufactures, and markets regenerative medicine products and medical devices for orthopedic and neurological surgeons in the United States and internationally. It is in Medical - Devices.
Does Xtant Medical Holdings pay a dividend?
No. Xtant Medical Holdings does not pay a dividend at the moment; in 2025 it returned $65,000 to shareholders by buying back its own shares.
Is Xtant Medical Holdings stock halal?
No. Xtant Medical Holdings does not pass our halal screen: its debt is 75% of its market value, at or above the 33% limit. How we check
How has Xtant Medical Holdings stock done over the past year?
Down 58.8% over the past twelve months, to $0.27. It traded between $0.27 and $0.81 and is 66.5% below its high.
Who are Xtant Medical Holdings's competitors?
The largest listed companies in the same industry are Boston Scientific, Koninklijke Philips, Steris and Zimmer Biomet Holdings. The peers table on this page compares their profit, growth and price with Xtant Medical Holdings's.
Prices: daily closes to Nov 13, 2026. Fundamentals: company reports via invest-like data.